AUS
NZ
UK
CA
USA
IND
Healthcare
Prescient Therapeutics Onboards Internationally Renowned CAR-T Expert Prof Phillip Darcy to Scientific Advisory Board
August 07, 2020 07:20 PM AEST| By Team Kalkine MediaAustralia based clinical-stage oncology company Prescient Therapeutics Limited (ASX:PTX) appointed globally renowned cancer and Chimeric Antigen Receptor-T (CAR-T) expert, Professor Phillip Darcy of Peter MacCallum Cancer Centre, to its Scientific .....
2 ASX Healthcare Stocks That have Skyrocketed Today - Lens on KZA & MXC
August 07, 2020 06:37 PM AEST| By Team Kalkine MediaSummary Kazia Therapeutics’ paxalisib awarded Rare Pediatric Disease Designation by the US FDA. With the RPDD grant, Kazia Therapeutics may now be eligible to receive a rare pediatric disease priority review voucher if paxalisib gets appr.....
.jpg)
Is Healthcare Rally Coming to an End? A needle on CSL, RMD, CUV
August 07, 2020 02:40 PM AEST| By Team Kalkine MediaCOVID-19 pandemic has stress-tested the world, and so far, affected more than 18.61 million people including 702,642 reported deaths (as per WHO 3:17 PM CEST, 6 August 2020). The Australian government’s response to the spread of SAR-C.....
All you need to know about 4DMedical
August 04, 2020 08:02 PM AEST| By Team Kalkine MediaSummary The healthcare sector has been a bright spot in the otherwise dull IPO market in 2020 with seven IPOs already and more in the pipeline. 4DMedical, the Melbourne-based MedTech player, is the latest entrant with ASX listing slated for 7 A.....
Up 100% in last 3 months, Genetic Technologies’ Share Grabs Further Attention
August 04, 2020 05:54 PM AEST| By Team Kalkine MediaSummary The periodic return on a stock is the major determinator for an investor to make an investment in it, be it in the form of dividends or capital appreciation. In the last 3 months period, GTG has given a positive return of 100% to the in.....
Prescient Therapeutics’ Progresses to Next Dose Level in PTX-200 AML Phase 1b Study
August 03, 2020 06:20 PM AEST| By Team Kalkine MediaSummary Prescient Therapeutics’ Phase 1b trial with PTX-200 in AML progresses to the next dose level of 35 mg/m2 PTX-200. Phase 1b study of PTX-200 at a dose of 25 mg/m2 demonstrated no dose-limiting toxicities and therapy was better tole.....
5 Pot Stocks and a Changed Perception: CAN, AC8, CGB, AGH, EOF
August 02, 2020 12:20 AM AEST| By Hina ChowdharyWhile healthcare and biotech companies are fighting to find a cure for COVID-19 to put an end to the global misfortune caused by the novel coronavirus cannabis stocks are grabbing attention with their continuous development amid the turmoil. The c.....
Can rising COVID-19 cases push these stocks further north? (RMD, FPH, ANN)
August 02, 2020 12:00 AM AEST| By Team Kalkine MediaSummary Australian Government’s response towards containing the Virus crisis was deemed successful worldwide. Amid the pandemic, healthcare companies supporting the healthcare regime through equipment and software solutions have rec.....
The emergence of Pro Medicus: How did the company grow sans external funding
August 01, 2020 01:06 AM AEST| By Hina ChowdharySummary Pro Medicus stock has gained over 4,6000%, from once trading at 50 cents per share to ~$24 per share, at present. PME’s Radiology platform Visage 7 has been the catalyst for the success of the Company, which allows medical images .....
Are these Healthcare Stocks for Brave Investors: Osprey, Clinuvel, Ramsay
July 31, 2020 10:59 PM AEST| By Kunal SawhneySummary GE Healthcare to exclusively distribute Osprey Medical Technology in Russia, Middle East, Central Asia, Europe, Africa, and Turkey. For the fourth quarter of FY20 CLINUVEL has cash receipts approximately A$10.40 million. Clinuvel conti.....
Two Stocks That Were Up Following Major Announcements - Mesoblast and Dimerix
July 30, 2020 08:25 PM AEST| By Team Kalkine MediaSummary Mesoblast disclosed that the Phase 3 clinical trial of Remestemcel-L is anticipated to complete recruitment in September 2020 in the US. At the end of the quarter ended June 2020, Mesoblast had nearly US$129.3 million cash on hand. Dim.....
Aged Care and COVID Outbreaks: Estia Health
July 29, 2020 05:47 PM AEST| By Kunal SawhneySummary New cases in Victoria are rising, and signs of small outbreaks in NSW are also noticeable. The infection has also hit aged care facilities, especially in Melbourne, Victoria. Federal Government has stepped in to tackle the crisis in age.....
Healthcare Space: Lens on ASX-listed Healius, Telix and Opthea
July 28, 2020 04:25 PM AEST| By Team Kalkine MediaWith a world-class healthcare system in place and continuous efforts from the government and medical experts, Australia has managed to curb the spread of SARS-CoV-2 outbreak. However, with the rising number of cases in Victoria, COVID-19 pandemic r.....
Prescient Therapeutics to Raise A$6.5 million Via SPP to Advance Clinical & Pre-clinical Programs
July 28, 2020 11:31 AM AEST| By Team Kalkine MediaPrescient Therapeutics (ASX:PTX), The ASX-listed biotechnology player developing targeted and personalised medicines for challenging cancers, announced a Share Purchase Plan (SPP) to raise nearly A$6.5 million. The Company intends to use this capit.....
MGC Pharmaceuticals under the Spotlight: Small-cap cannabis player makes significant announcements in July
July 27, 2020 02:52 PM AEST| By Team Kalkine MediaSummary EU biopharma player MGC Pharmaceuticals announced favourable safety and tolerability results for COVID-19 treatment candidate, ArtemiC in a preclinical study. The Company signed a binding term sheet with Cannvalate Pty Ltd to acquire 10.....
Healthcare Corner: Lens on CSL and Opthea
July 26, 2020 12:20 AM AEST| By Kunal SawhneySummary University of Queensland’s COVID-19 vaccine candidate, for which biotech player CSL is providing technical assistance, began human trials on 13 July 2020. CSL had earlier announced the acquisition of exclusive global license right.....
Prescient Therapeutics’ Dazzling June Quarter Report, Achieved Significant Milestones
July 23, 2020 11:43 AM AEST| By Team Kalkine MediaSummary In June 2020 quarter, Prescient added new assets in its belt with the most significant milestone of a next-generation immunotherapy platform ‘OmniCAR’. Prescient onboarded former Juno Executive Dr Allen Ebens, having a vast .....
Remarkable! Assets of Prescient Selected for COVID-19 Antiviral Testing Program by Doherty Institute
July 22, 2020 12:49 PM AEST| By Team Kalkine MediaClinical stage oncology company Prescient Therapeutics Limited (ASX:PTX) notified that two of its assets had been selected as Group 1 priority candidates for a COVID-19 antiviral testing program by Doherty Institute in Melbourne. Both assets of PTX.....
Did you miss the latest updates from small-cap healthcare players Recce and AnteoTech?
July 18, 2020 03:33 AM AEST| By Kunal SawhneyThe absence of a proven vaccine or treatment for COVID-19 has overshadowed the other challenges that we are currently facing relating the pandemic. With the ongoing surge in coronavirus cases, there is an urgent need to have advanced testing kits t.....
Imugene Receives Second Ethics Approval to Commence PD1-Vaxx Phase 1 Trial, Stock Soars 8%
July 17, 2020 03:04 PM AEST| By Team Kalkine MediaClinical stage immuno-oncology firm based in Australia, Imugene Limited (ASX:IMU) has received a second human research ethics approval from the Sydney-based Macquarie University Human Research Ethics Committee (HREC) to kickstart Phase I clinical t.....
Advertise your brand on Kalkine Media